fbpx

Science 37 Stock for Decentralized Clinical Trials

June 23. 2021. 7 mins read

Nothing like a pandemic to illuminate a thing or two about human nature. For example, people apparently spend way too much time wiping their butts. Or, at the very least, are very inefficient in their use of toilet paper. We also learned quite a bit about clinical trials, though the COVID-19 vaccine studies were atypical in many ways. Thousands of participants, for instance, eagerly signed up to participate so they could earn up to $2,000 contribute to the advancement of science. But that’s the exception, not the rule. About 85% of clinical trials fail to attract enough participants, despite the fact that pharmaceutical companies reportedly spend 40% of those research dollars on recruiting guinea pigs patients. On the flip side, it’s not very easy for patients to find clinical trials. Those failures and inefficiencies are driving a trend known as decentralized clinical trials. 

It’s yet another riff on the telehealth theme, which has hit warp speed over the last 16 months or so, with record amounts of funding pouring into the space. One example we recently wrote about is Babylon Health, which provides virtual healthcare through apps, chats, and video consultations. In the case of decentralized clinical trials, the idea is to shift away from brick-and-mortar sites to remotely controlled studies that allow patients to participate from home using digital tools like apps and wearables. 

A Los Angeles-based firm called Science 37 thinks it has the best p

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.